Skip to main content
Explore URMC

Peter Van Veldhuizen, M.D.

Contact Information

Phone Numbers

Appointment: (585) 276-3000

URMFGA member of the University of Rochester Medical Faculty Group

groupAn Accountable Health Partner

assignmentAccepting New Patients

Faculty Appointments

Patient Care Setting



Dr. Van Veldhuizen completed his residency training followed by a Hematology/ Oncology fellowship at the University of Kansas Medical Center. He is board-certified in Internal Medicine, Hematology, and Oncology. After spending much of his career in Kansas City where his primary clinical focus was the treatment of Genitourinary Malignancies (GU), in 2020 he joined the University of Rochester and the Wilmot Cancer Center to lead their GU Medical Oncology Program.

Dr. Van Veldhuizen sees patients with kidney, bladder, testicular, and prostate cancer. He is involved in helping formulate multidisciplinary treatment plans, administering chemotherapy, and managing symptoms related to both the cancer and its treatment. He also has a clinical focus on cancer survivorship and addressing all aspects related to the cancer diagnosis.

Professional Background

Dr. Van Veldhuizen is a Professor of Internal Medicine at the University of Rochester Medical Center and currently leads the GU Medical Oncology Program. He also serves as the chair of the Genitourinary Working Group which provides oversight and direction for the GU Clinical Trial Research Program. He also currently serves on the American Society of Clinical Oncology's (ASCO) Clinical Guidelines Committee which provides treatment guidelines for practicing Oncologists. He has served as a grant reviewer for the Department of Defense Prostate Cancer Research Program and is currently a committee member for an ASCO expert panel focusing on developing treatment guidelines for advanced kidney cancer.
Before coming to Rochester, he served as chair of the Kansas City Veteran Affairs Hematology/Oncology Program and then served as the Division Director of Hematology/ Oncology at the University of Kansas Medical Center. He is an advocate for addressing all aspects of the cancer diagnosis.


Dr. Van Veldhuizen's research has focused on the development of novel clinical trials for the treatment of genitourinary malignancies. He has been a member of the National Clinical Trial Group, SWOG, and their Genitourinary Cancer (GU) Committee since 1992. He currently serves on their GU Executive Committee and is the Chairman of SWOG's GU Cancer Survivorship Subcommittee. He also serves as the GU liaison to the Cancer Control Committees helping mentor investigators in the development of Cancer Control and Survivorship projects. He has been the national Principal Investigator (PI) or primary coordinator on SWOG trials and well as the PI on local investigator-initiated studies. He has had a focused interest in collaborating with laboratory-based scientists, helping translate those findings into the clinic. His current laboratory-based research interest is evaluating the mechanism of the spread of prostate cancer to the bone.



  • Hematology - American Board of Internal Medicine
  • Medical Oncology - American Board of Internal Medicine


MD | University of South Dakota School of Medicine

Post-doctoral Training & Residency

6/30/1986 - 6/30/1987
Internship in Internal Medicine at University of Kansas Medical Center

06/30/1989 - 06/30/1992
Fellowship in Medical Oncology at University of Kansas Medical Center

06/30/1987 - 06/30/1989
Residency in Internal Medicine at University of Kansas Medical Center

VIEW ALL expand_more


Journal Articles

Motzer R, Alekseev B, Rha SY, Porta C, Eto M, Powles T, Grünwald V, Hutson TE, Kopyltsov E, Méndez-Vidal MJ, Kozlov V, Alyasova A, Hong SH, Kapoor A, Alonso Gordoa T, Merchan JR, Winquist E, Maroto P, Goh JC, Kim M, Gurney H, Patel V, Peer A, Procopio G, Takagi T, Melichar B, Rolland F, De Giorgi U, Wong S, Bedke J, Schmidinger M, Dutcus CE, Smith AD, Dutta L, Mody K, Perini RF, Xing D, Choueiri TK, . "Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma." The New England journal of medicine.. 2021 Apr 8; 384(14):1289-1300. Epub 2021 Feb 13.

Choueiri TK, Powles T, Burotto M, Escudier B, Bourlon MT, Zurawski B, Oyervides Juárez VM, Hsieh JJ, Basso U, Shah AY, Suárez C, Hamzaj A, Goh JC, Barrios C, Richardet M, Porta C, Kowalyszyn R, Feregrino JP, ?o?nierek J, Pook D, Kessler ER, Tomita Y, Mizuno R, Bedke J, Zhang J, Maurer MA, Simsek B, Ejzykowicz F, Schwab GM, Apolo AB, Motzer RJ, . "Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma." The New England journal of medicine.. 2021 Mar 4; 384(9):829-841.

D'souza A, Van Veldhuizen P, Fung C. "Surviving Testicular Cancer: The Role of the Contralateral Testicle." Journal of clinical oncology : official journal of the American Society of Clinical Oncology.. 2021 Feb 1; 39(4):265-268.